Skip to main content
S&P 5007,610.34+0.32%DOW52,028.07-0.12%NASDAQ26,153.23+0.66%BTC$75,823.00-0.63%ETH$2,399.06-1.94%GOLD$4,386.20+1.23%OIL$103.57-2.14%
Smart Investors Daily
GM

NYSE · GMAB

Genmab A/S

Healthcare · Biotechnology

$34.15

Up+$0.23 (+0.67%)

Updated Sep 16, 2026, 1:42 PM

SID Score

7.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
19.89B
P/E ratio
14.56
Dividend yield
0.00%
52-week range
$23.62 – $35.43
Volume
3.09M
Avg. volume
2.09M

Price performance

GMAB price history

1M range · 20 trading sessions · Daily adjusted prices

GMAB closed at $34.15 after 20 trading sessions, up 3.61% for the selected period.

Last close
$34.15
Period change
+3.61%
Period low
$32.23
Period high
$34.41
Daily close
View OHLC price history
GMAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$32.34$34.185$32.34$34.153.09M
Sep 14, 2026$32.79$32.96$32.52$32.651.41M
Sep 11, 2026$32.45$32.70$32.27$32.471.39M
Sep 10, 2026$32.46$32.68$32.21$32.231.02M
Sep 9, 2026$33.47$33.75$32.98$33.042.13M
Sep 8, 2026$33.71$33.84$33.36$33.531.55M
Sep 4, 2026$33.96$34.19$33.545$33.601M
Sep 3, 2026$34.63$34.66$34.08$34.41890.95K
Sep 2, 2026$34.04$34.50$33.74$34.2152.08M
Sep 1, 2026$33.33$33.67$33.15$33.291.56M
Aug 31, 2026$32.76$33.26$32.5401$33.161.73M
Aug 28, 2026$33.78$33.9295$33.115$33.231.52M
Aug 27, 2026$33.91$34.165$33.67$34.101.87M
Aug 26, 2026$33.78$33.90$33.36$33.753.09M
Aug 25, 2026$33.81$34.4699$33.72$34.362.03M
Aug 24, 2026$32.82$33.32$32.74$33.023.25M
Aug 21, 2026$33.36$33.98$33.28$33.452.54M
Aug 20, 2026$33.60$33.77$33.20$33.416.35M
Aug 19, 2026$33.41$34.185$33.255$34.113.23M
Aug 18, 2026$32.86$33.11$32.66$32.962.71M

Latest GMAB news

The latest Smart Investors Daily articles mentioning GMAB.

Stock researchCompany · Overview

GMAB research

Overview

Company profile and research snapshot.

Company profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.25
Implied upside
—
Analysts
—
GMAB recent ratings
DateFirmRatingTarget
Jul 13, 2026ROTHSCHILD & CO REDBURNBuy—
Jul 13, 2026JYSKE BANKBuy—
Jul 12, 2026TD COWENHold—
Jul 12, 2026H.C. WAINWRIGHT & CO., LLCBuy—
Jul 7, 2026DNB CARNEGIEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,409 shares at DKK 1,334.50,1,464 shares at DKK 1,362.50,20,270 shares at DKK 1,615.00, and1,868 shares at DK

Yahoo · Sep 8, 2026

Notice to Convene an Extraordinary General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on Wednesday, October 7, 2026, at 3:00 PM CEST at Genmab's offices, Carl Jacobsens Vej 30, 2500 Valby, Denmark. The notice for the Extraordinary General Meeting, including Appendix 1: Shareholder Letter, is attached. Shareholders are encouraged to visit Genmab’s website at Gen

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By